Inflammatory Marker sTREM-1 Reflects the Clinical Stage and Respiratory Tract Obstruction in Allergic Asthma Bronchiale Patients and Correlates with Number of Neutrophils

Table 2

Plasma levels of sTREM-1 in healthy subjects and asthma bronchiale patients.

Patients	Age (years) (mean ± STD)	sTREM-1 (pg/mL) (Median)	sTREM-1 (IQR)	Mann-Whitney (2-tailed) 𝑃
Healthy subjects	37.3 ± 13.7	25.7	9.2
AB patients	37.4 ± 21.4	92.3	125.6	<0.0001
Mild intermittent AB (AB1)	22.0 ± 10.6	50.8	49.2
Mild persistent AB (AB2)	29.7 ± 15.7	75.7	87.7	=0.333^*
Moderate persistent AB (AB3)	48.1 ± 26.2	145.6	111.4	=0.001^*
Severe persistent AB (AB4)	55.5 ± 9.7	244.0	201.8	<0.005^*
Kruskal-Wallis 2-tailed sg.	𝑃<0.005
EAB	54.7 ± 19.0	170.5	78.2
NEAB	30.0 ± 18.2	59.1	78.2	<0.0001^**
Respiratory tract obstruction (RTO^+)	52.1 ± 19.2	176.4	177.8
Without RTO (RTO^−)	24.7 ± 13.0	52.0	64.0	<0.0001^**
Anti-IgE therapy	54.1 ± 13.0	163.4	180.1
Without anti-IgE therapy	34.6 ± 21.2	76.9	104.3	<0.0001^**

AB: asthma bronchiale, STD: standard deviation, IQR: interquartile range, ^*significance between AB2 versus AB1, AB3 versus AB1, AB4 versus AB1, EAB: exacerbated asthma bronchiale, NEAB: non-exacerbated asthma bronchiale, RTO⁺: asthma with respiratory tract obstruction, RTO⁻: asthma without respiratory tract obstruction, ^**significance between exacerbated versus non-exacerbated asthma, asthma with versus without respiratory tract obstruction, patients with versus without anti-IgE therapy.